Shi Xiao, Li Ruibo, Shi Xiaoyi, Yan Yuxing, Gong Aixia
Department of Gastroenterology, First Affiliated Hospital, Dalian Medical University, Dalian, China.
Department of Gastroenterology, the Second People's Hospital of Liaocheng, Liaocheng, China.
Scand J Gastroenterol. 2025 Feb;60(2):136-142. doi: 10.1080/00365521.2024.2449072. Epub 2025 Jan 8.
The Charlson Comorbidity Index (CCI) and prognostic nutritional index (PNI) have proven to be valuable tools in predicting prognosis based on comorbidities and nutritional status in the context of surgical procedures and endoscopic resections. The age-Adjusted CCI (ACCI) has also shown utility in surgical settings, but its application to early gastric cancer (EGC) remains unexplored. Consequently, we aimed at clarifying the prognostic factors for EGC treated with endoscopic submucosal dissection (ESD).
Patients who underwent ESD for EGC at the First Affiliated Hospital of Dalian Medical University from January 2015 to February 2023 were included. The overall survival (OS) and prognostic predictive ability were evaluated based on patients and lesion characteristics.
During a median follow-up period of 50 months, 15 patients died, but none from the gastric cancer. The 5-year survival rate was 90.0%. In univariate and multivariate analyses, a high ACCI (>4.5) was the only significant prognostic factor (Hazard ratio, 27.78; 95% confidence interval, 3.62-213.40; < 0.01). The 5-year survival rates for patients with low ACCI (<4.5) and high ACCI were 98.9% and 72.9%, respectively ( < 0.01).
A high ACCI is a significant prognostic indicator for 5-year survival and the risk of mortality caused by other comorbidities. EGC suitable for ESD is unlikely to serve as a prognostic factor, and ACCI should be considered as an important reference when considering additional surgical procedures in high-ACCI patients after ESD with endoscopic curability (eCura) C-2 for EGC.
在外科手术和内镜切除的背景下,查尔森合并症指数(CCI)和预后营养指数(PNI)已被证明是基于合并症和营养状况预测预后的有价值工具。年龄调整后的CCI(ACCI)在外科手术环境中也显示出实用性,但其在早期胃癌(EGC)中的应用仍未得到探索。因此,我们旨在阐明内镜黏膜下剥离术(ESD)治疗EGC的预后因素。
纳入2015年1月至2023年2月在大连医科大学附属第一医院接受ESD治疗EGC的患者。根据患者和病变特征评估总生存期(OS)和预后预测能力。
在中位随访期50个月期间,15例患者死亡,但均非死于胃癌。5年生存率为90.0%。在单因素和多因素分析中,高ACCI(>4.5)是唯一显著的预后因素(风险比,27.78;95%置信区间,3.62 - 213.40;P < 0.01)。低ACCI(<4.5)和高ACCI患者的5年生存率分别为98.9%和72.9%(P < 0.01)。
高ACCI是5年生存率和其他合并症导致死亡风险的显著预后指标。适合ESD的EGC不太可能作为预后因素,在EGC内镜治愈性(eCura)C - 2级ESD后考虑对高ACCI患者进行额外手术时,应将ACCI视为重要参考。